www. Buy Cialis Online - 7menshealth.com

“What to Do about Erectile Dysfunction”, the new report from Harvard Medical School says that temporary erectile problems could be also caused by riding a bike for long periods. Cycle more than three hours a week may increase that risk.Temporary Erectile Dysfunction takes a place while cycling, because bike seat puts pressure on the perineum, what is the place between genitals and the anus. This pressure is responsible for harming nerves what cause temporarily decrease in blood flow what leads to pins and needles the penis and sometimes to the erectile dysfunction. There is a study which shows very interesting thing that a recumbent bicycle instead of regular one doesn’t cause degrease in amount of oxygen supply to the penis.

If you want to get ride of cycling-connected erectile problems and you don’t want to change to a recumbent bike you should follow these precautions:

• Remember to wear padded biking shorts.
• Raise the handlebars so that you’re sitting relatively upright to degrease pressure from perineum and ‘move’ it to the buttocks.
• It is recommended to use wide, soft or gel-filled seat instead of hard and narrow ones, this will reduce the pressure on the perineum.
• Ensure that your seat is well-regulated before ride, you should be able to have your legs fully extended at the bottom of your pedal stroke. However remember to do not tilt the seat up.
• While you riding for long time, it is advised to taking breaks and changing the position during ride.
• Stop cycling for a week or two if you feel tingling or numbness in the penis, this is the warning that you have been riding too much.

“What to Do about Erectile Dysfunction” is a 32-page report edited by Michael Philip O’Leary, M.D., Ph.D., associate professor at Harvard Medical School. This report explains:

• The physiology and anatomy of regular sexual activity and erectile problems,
• The causes of erectile dysfunction, including a self-assessment questionnaire
• The different available treatment methods (including alternatives to Viagra, Cialis and similar drugs)
• The role of advisory service
• How to involve your partner to help you deal with this problem of erectile dysfunction.

Saturday January 20, 2007

Researchers predict that one third of older men suffering from erectile dysfunction will feel improvement, which does not mean, however, that the symptoms will disappear – they will be less acute.

At the same time, however, one third will feel that their condition has worsened.

In the Journal of Urology we can find information that erectile dysfunction, or impotence, may affect even more than 150 million of men. Erectile dysfunction has been a topical issue over the last few years, because of its prevalence and new ways of treatment, for example Viagra. There is, however, little knowledge concerning the development of the illness after onset.

In Massachusetts Male Ageing Study, data for 401 men with different degrees of impotence, aged between 40 and 70, were collected for 9 years.

According to Dr Thomas G. Travison from New England Research Institutes in Watertown, Massachusetts, the analysis of the data revealed a surprisingly high percentage of men who experienced natural remission of erectile dysfunction.

The improvement concerned 141 men, which constitutes 35 per cent.

Disappointingly, the symptoms worsened in 107 men, which constitute 33 per cent. The situation of 45 of 78 men (58 per cent) with complete erectile dysfunction did not alter.

It was noticed that the older and heavier the men, the smaller chance of natural remission.

Smoking and poor general condition were also the causes of worsening of impotence.

The gist of the research, according to Dr Travison, is the confirmation of the fact that keeping fit, being healthy and active, helps maintain, or sometimes even improve, male sexual abilities.

There is great news for manufacturer of Cialis, because its product peak the level of $269.2 million in the fourth quarter what means a 28 percent rise according to the last year.

According to a Thursday’s statement made by medicine makers Eli Lilly & Co. and Bothell-based Icos, who co-market Cialis, this product made $746 million income in 2005 and then $971 million in worldwide sales in 2006.

Lilly Icos said that rise of the profit $320.3 million in 2006 towards $37.8 million in the year before is merit of that sales goes up and companies don’t have to spend so much money on the advertisements of the product.

In 2006 sales Icos sales forecast was estimated at $955 million, however Cialis, with price about $12 per pill beat this number and reach $965 million. Forecasts for the year 2007 are estimated about $1.1 billion. According to the IMS Health, the drug market researchers, Cialis holds about 27 percent of the U.S. market, trailing only Viagra produced by Pfizer.

Chris Raymond, analyst with Robert W. Baird in Chicago, said: “They beat our numbers in the U.S., they beat them in Europe, in Canada, Mexico and the rest of the world”. He had also forecasted $240 million in worldwide fourth-quarter Cialis sales. “It’s clear why people think Lilly is getting a good deal,” he claims.

Raymond based his forecasts on the offer made by Eli Lilly to the Icos. Indianapolis-based drug maker would give Icos $34 a share or $2.28 billion for acquiring it. This deal would give Eli Lilly overall control on the Cialis’ market and eliminate the need to split profits with Icos.

On the Jan. 25 Icos shareholders will vote for or against the transaction.

HealthCor Management, a company based in New York which had about 5 percent of Icos shares said that price offered by Eli Lilly is to low and the company is worth at least $40 per share. Its estimations based on the rising popularity of Cialis and its potential to treat enlarged prostate and pulmonary arterial hypertension.

In February Lilly Icos, forecasted a profit from whole year would be about $210 million to $240 million. However Cialis’ performance beat all forecasts by raising its annual forecast two more times during the year, what beat the highest forecast made by Lilly Icos.

John Schroer, a member of the HealthCor investment team said: “Once again, the guidance that Icos gave on Dec. 14 proved to be overly conservative,” and he also added: “It reinforces the HealthCor position that Icos is worth substantially more than the current Lilly proposal of $34 a share.”